As of 2025-06-01, the Intrinsic Value of Celon Pharma SA (CLN.WA) is (21.52) PLN. This CLN.WA valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 22.00 PLN, the upside of Celon Pharma SA is -197.80%.
The range of the Intrinsic Value is (34.74) - (15.93) PLN
Based on its market price of 22.00 PLN and our intrinsic valuation, Celon Pharma SA (CLN.WA) is overvalued by 197.80%.
Note: result may not be accurate due to the invalid valuation result of DCF model.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (34.74) - (15.93) | (21.52) | -197.8% |
| DCF (Growth 10y) | (16.16) - (32.33) | (21.00) | -195.5% |
| DCF (EBITDA 5y) | (3.81) - (3.29) | (1,234.50) | -123450.0% |
| DCF (EBITDA 10y) | (6.16) - (4.56) | (1,234.50) | -123450.0% |
| Fair Value | -4.07 - -4.07 | -4.07 | -118.51% |
| P/E | (12.72) - (14.82) | (14.21) | -164.6% |
| EV/EBITDA | 2.01 - 4.55 | 3.05 | -86.1% |
| EPV | 10.74 - 13.15 | 11.95 | -45.7% |
| DDM - Stable | (8.72) - (26.53) | (17.63) | -180.1% |
| DDM - Multi | (5.53) - (13.05) | (7.76) | -135.3% |
| Market Cap (mil) | 1,184.92 |
| Beta | 0.44 |
| Outstanding shares (mil) | 53.86 |
| Enterprise Value (mil) | 1,181.35 |
| Market risk premium | 6.34% |
| Cost of Equity | 8.65% |
| Cost of Debt | 7.51% |
| WACC | 8.61% |